Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process.

OBJECTIVE

To evaluate the effect and safety of a low dose Filgrastim treatment in surgical intensive care patients.

DESIGN

Prospective, clinical study.

SETTING

Surgical intensive care unit (ICU) in a university hospital.

PATIENTS

Ten patients with the systemic inflammatory response syndrome (SIRS) and ten patients with sepsis were included in the study.

INTERVENTIONS

Filgrastim was given intravenously at 1.0 microgram/kg for 3 days, followed by 0.5 microgram/kg for 4 days.

MEASUREMENTS AND RESULTS

Filgrastim treatment increased leukocyte counts and plasma levels of G-CSF. Cytokine levels (IL-6 and IL-8) decreased in the first 3 days of treatment. None of the SIRS patients developed sepsis or multiple organ failure and none of the patients died. In the sepsis group four patients died. No adverse side effects were observed, especially no attenuation of lung injury.

CONCLUSIONS

Low-dosage Filgrastim treatment in ICU patients is safe. Whether the observed changes of the inflammatory response can be attributed to Filgrastim has to be clarified in further randomized trials.